Europe Anti diabetic Biosimilars Market: By Drug Class -IV Inhibitors, glucosidase Inhibitos, GLP-1 Agonists, SGLT-2 Inhibitors, Others), By Disease Type, By Distribution Channel and Geography  

download arrow download arrow Download Free Sample
settings arrow settings arrow email us

Europe Anti diabetic Biosimilars Market: By Drug Class (Insulin, Biguanides, Sulfonyl Ureas, Thiazolidinediones, Di Peptidyl Peptidase (DPP)-IV Inhibitors, glucosidase Inhibitos, GLP-1 Agonists, SGLT-2 Inhibitors, Others), By Disease Type (Type-I Diabetes, Type-II Diabetes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography  

checked icon arrow_drop_down
checked icon Single User License $3100 $2480
checked icon Multiple User License $4600 $3680
checked icon Corporate User License $6900 $5520

Europe Anti diabetic Biosimilars Market size was valued at US$ x million in 2023 and is poised to grow at a CAGR of x% from 2024 - 2030. Biosimilars are biological substances that are highly similar to biologics but not identical to patented biological molecules. These are manufactured after the patent expiration of original products. Anti-diabetic biosimilars help to control the blood glucose levels in diabetic patients. Commonly used anti-diabetic drugs include biguanides, sulfonylureas, GLP-1 receptor agonists, DPP-IV inhibitors, thiazolidinediones, and insulin among others. These are cost-effective molecules with similar potency and efficiency compared with reference biological molecules.

High cost and longer duration of R&D activities, Stringent regulatory policies, and Complexity in the development of biosimilars are restraints of the Europe Antidiabetic Biosimilars Market. This report presents market dynamics elaborately to identify the current market trends & drivers, future opportunities, and possible challenges to the key stakeholders operating in the market. In addition, the market report includes a competition analysis with a vividly illustrated competition dashboard to assess the market competition. Key stakeholders of the market report include raw material suppliers, manufacturers, marketers, policymakers, and healthcare service providers, who are engaged in the usage and advocacy of Antidiabetic biosimilar products.

Europe Anti diabetic Biosimilars Market Dynamics

Increase in the prevalence of diabetic patients due to change in lifestyle, Patent expiries block buster drugs and promising product pipeline and Rise in R&D activities for the innovation of Insulin biosimilars are driving Europe Anti diabetic Biosimilars Market.

Europe Anti Diabetic Biosimilars Market Segmentation Analysis

Report Benchmarks

Details

By Drug Class

  • Insulin
  • Biguanides
  • Sulfonyl Ureas
  • Thiazolidinediones
  • Di Peptidyl Peptidase (DPP)-IV Inhibitors
  • ?-glucosidase Inhibitos
  • GLP-1 Agonists
  • Others

By Disease Type

  • Type-I Diabetes
  • Type-II Diabetes

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

2023 is the base year and 2030 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1. Executive Summary
2. Europe Anti diabetic Biosimilars Market Introduction 
2.1. Europe Anti diabetic Biosimilars Market  - Taxonomy
2.2. Europe Anti diabetic Biosimilars Market  - Definitions
2.2.1.Drug Class 
2.2.2.Disease Type
2.2.3.Distribution Channel
2.2.4.Region
3. Europe Anti diabetic Biosimilars Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Europe Anti diabetic Biosimilars Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Europe Anti diabetic Biosimilars Market  By Drug Class , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Insulin
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Biguanides
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Sulfonyl Ureas
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Thiazolidinediones
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Di Peptidyl Peptidase (DPP)-IV Inhibitors
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
5.6. glucosidase Inhibitos
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.6.3. Market Opportunity Analysis 
5.7. GLP-1 Agonists
5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.7.3. Market Opportunity Analysis 
5.8. Others
5.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.8.3. Market Opportunity Analysis 
6. Europe Anti diabetic Biosimilars Market  By Disease Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Type-I Diabetes
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Type-II Diabetes
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
7. Europe Anti diabetic Biosimilars Market  By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Online Pharmacies
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8. Europe Anti diabetic Biosimilars Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Europe Anti diabetic Biosimilars Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Drug Class  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Insulin
9.1.2.Biguanides
9.1.3.Sulfonyl Ureas
9.1.4.Thiazolidinediones
9.1.5.Di Peptidyl Peptidase (DPP)-IV Inhibitors
9.1.6.glucosidase Inhibitos
9.1.7.GLP-1 Agonists
9.1.8.Others
9.2.  Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Type-I Diabetes
9.2.2.Type-II Diabetes
9.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital Pharmacies
9.3.2.Retail Pharmacies
9.3.3.Online Pharmacies
9.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10. Europe Europe Anti diabetic Biosimilars Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Drug Class  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Insulin
10.1.2.Biguanides
10.1.3.Sulfonyl Ureas
10.1.4.Thiazolidinediones
10.1.5.Di Peptidyl Peptidase (DPP)-IV Inhibitors
10.1.6.glucosidase Inhibitos
10.1.7.GLP-1 Agonists
10.1.8.Others
10.2.  Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Type-I Diabetes
10.2.2.Type-II Diabetes
10.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital Pharmacies
10.3.2.Retail Pharmacies
10.3.3.Online Pharmacies
10.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
10.4.7.
11. Asia Pacific (APAC) Europe Anti diabetic Biosimilars Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Drug Class  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Insulin
11.1.2.Biguanides
11.1.3.Sulfonyl Ureas
11.1.4.Thiazolidinediones
11.1.5.Di Peptidyl Peptidase (DPP)-IV Inhibitors
11.1.6.glucosidase Inhibitos
11.1.7.GLP-1 Agonists
11.1.8.Others
11.2.  Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Type-I Diabetes
11.2.2.Type-II Diabetes
11.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital Pharmacies
11.3.2.Retail Pharmacies
11.3.3.Online Pharmacies
11.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12. Middle East and Africa (MEA) Europe Anti diabetic Biosimilars Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Drug Class  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Insulin
12.1.2.Biguanides
12.1.3.Sulfonyl Ureas
12.1.4.Thiazolidinediones
12.1.5.Di Peptidyl Peptidase (DPP)-IV Inhibitors
12.1.6.glucosidase Inhibitos
12.1.7.GLP-1 Agonists
12.1.8.Others
12.2.  Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Type-I Diabetes
12.2.2.Type-II Diabetes
12.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital Pharmacies
12.3.2.Retail Pharmacies
12.3.3.Online Pharmacies
12.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13. Latin America Europe Anti diabetic Biosimilars Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Drug Class  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Insulin
13.1.2.Biguanides
13.1.3.Sulfonyl Ureas
13.1.4.Thiazolidinediones
13.1.5.Di Peptidyl Peptidase (DPP)-IV Inhibitors
13.1.6.glucosidase Inhibitos
13.1.7.GLP-1 Agonists
13.1.8.Others
13.2.  Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Type-I Diabetes
13.2.2.Type-II Diabetes
13.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital Pharmacies
13.3.2.Retail Pharmacies
13.3.3.Online Pharmacies
13.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Merck Sharp & Dohme Corporation (U.S.)
14.2.2.Boehringer Ingelheim GmbH (Germany)
14.2.3.Eli Lilly & Co. (U.S.)
14.2.4.Sanofi-aventis U.S. LLC (U.S.)
14.2.5.Samsung Bioepis (Samsung BioLogics) (South Korea)
14.2.6.Mylan N.V. (U.S.)
14.2.7.Wockhardt (India)
15. Research Methodology 
16. Appendix and Abbreviations 

Key Market Players

  • Merck Sharp & Dohme Corporation (U.S.)
  • Boehringer Ingelheim GmbH (Germany)
  • Eli Lilly & Co. (U.S.)
  • Sanofi-aventis U.S. LLC (U.S.)
  • Samsung Bioepis (Samsung BioLogics) (South Korea)
  • Mylan N.V. (U.S.)
  • Wockhardt (India)

Related Industry Reports

Chronic Refractory Gout Pharmaceuticals Market

Familial Mediterranean Fever Pharmaceuticals Market

Australia Point of Care Diagnostics Market

Aseptic Sampling Market